161 related articles for article (PubMed ID: 36181655)
1. AVT02: An Adalimumab Biosimilar.
Kang C
Clin Drug Investig; 2022 Oct; 42(10):875-878. PubMed ID: 36181655
[TBL] [Abstract][Full Text] [Related]
2. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
Feldman SR; Reznichenko N; Pulka G; Kingo K; George Galdava ; Berti F; Sobierska J; Dias R; Guenzi E; Hendrik Otto ; Haliduola HN; Kay R; Stroissnig H
BioDrugs; 2021 Nov; 35(6):735-748. PubMed ID: 34657274
[TBL] [Abstract][Full Text] [Related]
4. PF-06410293: An Adalimumab Biosimilar.
Lee A; Shirley M
BioDrugs; 2020 Oct; 34(5):695-698. PubMed ID: 32949384
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Interchangeability of AVT02 and Humira
Feldman SR; Kay R; Reznichenko N; Sobierska J; Dias R; Otto H; Haliduola HN; Sattar A; Ruffieux R; Stroissnig H; Berti F
BioDrugs; 2023 Jul; 37(4):551-567. PubMed ID: 37204631
[TBL] [Abstract][Full Text] [Related]
6. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
7. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
Wynne C; Schwabe C; Lemech C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Kay R; Haliduola HN; Berti F
Expert Opin Investig Drugs; 2022 Sep; 31(9):965-976. PubMed ID: 35107050
[TBL] [Abstract][Full Text] [Related]
8. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
[TBL] [Abstract][Full Text] [Related]
9. GP2017: An Adalimumab Biosimilar.
Heo YA
BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
[TBL] [Abstract][Full Text] [Related]
10. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
[TBL] [Abstract][Full Text] [Related]
11. PB006: A Natalizumab Biosimilar.
Shirley M
Clin Drug Investig; 2024 May; 44(5):367-370. PubMed ID: 38683493
[TBL] [Abstract][Full Text] [Related]
12. FKB327: An Adalimumab Biosimilar.
Al-Salama ZT
BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
[TBL] [Abstract][Full Text] [Related]
13. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
14. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
Menter A; Cohen S; Kay J; Strand V; Gottlieb A; Hanauer S; Eduru SK; Buschke S; Lang B; Liesenfeld KH; Schaible J; McCabe D
Am J Clin Dermatol; 2022 Sep; 23(5):719-728. PubMed ID: 35934770
[TBL] [Abstract][Full Text] [Related]
15. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
Menter A; Arenberger P; Balser S; Beissert S; Cauthen A; Czeloth N; Soung J; Jazayeri S; Weisenseel P; Jayadeva G
Expert Opin Biol Ther; 2021 Jan; 21(1):87-96. PubMed ID: 33317345
[No Abstract] [Full Text] [Related]
16. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
Zhou X; Chen Z; Bi X
Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
[TBL] [Abstract][Full Text] [Related]
18. PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT
BioDrugs; 2018 Dec; 32(6):639-642. PubMed ID: 30284704
[TBL] [Abstract][Full Text] [Related]
19. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
[TBL] [Abstract][Full Text] [Related]
20. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi
Gisbert JP; Gaffney K; Young D; Ebbers HC; Girolomoni G
Expert Opin Biol Ther; 2022 Feb; 22(2):109-121. PubMed ID: 34918591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
